Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.61 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.61 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.61 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.61 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.61 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.61 |
| ▸ | BCHE | P06276 | 6/20 | 0.60 |
| ▸ | ACHE | P22303 | 6/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.59 |
| ▸ | HTR2A | P28223 | 1/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.55 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 2/20 | 0.53 |
| ▸ | DRD3 | P35462 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24746501 | 0.86 | ADRA2A (0.66) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL24746500 | 0.84 | HPGD (0.66) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL5336211 | 0.83 | HTR2A (0.64) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL5331541 | 0.81 | HTR2A (0.68) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL5335494 | 0.81 | HTR2A (0.68) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL24746502 | 0.80 | HPGD (0.69) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL10854033 | 0.80 | ADRA2A (0.77) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL24746503 | 0.80 | HTR2A (0.74) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL24746495 | 0.79 | ADRA2A (0.69) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL5332152 | 0.79 | HTR2A (0.65) | ADRA2AADRA2BADRA2CADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357146-A1 | PRODRUGS AND CONJUGATES OF DIMETHYLTRYPTAMINE | ATAI THERAPEUTICS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230357146-A1 | PRODRUGS AND CONJUGATES OF DIMETHYLTRYPTAMINE | ATAI THERAPEUTICS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-11643391-B2 | Prodrugs and conjugates of dimethyltryptamine | ATAI THERAPEUTICS, INC. | 2023-05-09 | — | — | US | disclosed |
| US-11643391-B2 | Prodrugs and conjugates of dimethyltryptamine | ATAI THERAPEUTICS, INC. | 2023-05-09 | — | — | US | disclosed |
| US-20230041584-A1 | NOVEL PRODRUGS AND CONJUGATES OF DIMETHYLTRYPTAMINE | ATAI THERAPEUTICS, INC. | 2023-02-09 | — | — | US | disclosed |
| WO-2022261383-A1 | NOVEL PRODRUGS AND CONJUGATES OF DIMETHYLTRYPTAMINE | ATAI Life Sciences AG (DE) | 2022-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230041584-A1 | NOVEL PRODRUGS AND CONJUGATES OF DIMETHYLTRYPTAMINE | NPY1R, NPY5R, HTR1A | ADRA2A 126/4885ADRA2B 127/4885ADRA2C 142/4885 |
| US-20230357146-A1 | PRODRUGS AND CONJUGATES OF DIMETHYLTRYPTAMINE | NPY1R, NPY5R, NPY2R | ADRA2A 115/4885ADRA2B 131/4885ADRA2C 139/4885 |
| US-11643391-B2 | Prodrugs and conjugates of dimethyltryptamine | NPY1R, NPY5R, NPY2R | ADRA2A 115/4885ADRA2B 131/4885ADRA2C 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.